Using a special microscope during colonoscopy to predict treatment response in ulcerative colitis
Part of Digestive system clinical trials.
This study looks at whether a special microscope used during a colonoscopy can help predict how well your ulcerative colitis will respond to a new type of medication called a small molecule. If you're starting this treatment, the results might tell you early if it's likely to work for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have had ulcerative colitis for at least 12 weeks.
- Your colitis must be active, meaning you have symptoms like frequent bowel movements or rectal bleeding.
- You must be about to start or have recently started a type of medication called a 'small molecule' (like tofacitinib) for your colitis.
- You cannot be pregnant (or planning pregnancy) during the study.
- You must not have an allergy to fluorescein dye, which is used during the special microscope exam.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This study compares different special camera techniques during colonoscopy to see which best finds early abnormal (pre-cancer) changes in people with long-term ulcerative colitis. It may help doctors improve how they screen and monitor your colon over time.
This study looks at new ways to detect scarring (fibrosis) in the bowel using advanced imaging and tests. It may help doctors better understand and monitor ulcerative colitis. If you are already having a colonoscopy, you may be able to join.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This study tests a new way to monitor ulcerative colitis using stool tests and colonoscopy to detect early signs of cancer. It may help doctors manage long-term ulcerative colitis more safely.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.